一分钟看懂
这是一项关于前列腺癌的I 期 / II 期研究，登记的药物或干预包括HRS-5041 tablets；Abiraterone Acetate tablets（II）；Prednisone Acetate tablets；Docetaxel Injection；HRS-1167 tablets；SHR2554 tablets；HRS-6208 ca，当前状态为招募中。登记地点显示中国哈尔滨、上海有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
HRS-5041 tablets；Abiraterone Acetate tablets（II）；Prednisone Acetate tablets；Docetaxel Injection；HRS-1167 tablets；SHR2554 tablets；HRS-6208 capsules；HRS-2189 Tablets · I 期 / II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- The Second Affiliated Hospital of Harbin Medical University · 哈尔滨
- Shanghai Jiao Tong University School of Medicine, Renji Hospital · 上海
公开的入选条件
- 1. Have the ability to give informed consent, and are willing and able to comply with planned visits for medical examinations and other procedural requirements.
- 2. The age is above 18 years old when signing the informed consent (the ceiling age is 80 years old in the dose escalation phase), male.
- 3. ECOG score is 0 or 1.
- 4. An expected survival of ≥ 12 weeks.
- 5. Adenocarcinoma of the prostate confirmed with histologically or cytologically ,and without a diagnosis of neuroendocrine or small cell carcinoma.
- 6. Adequate blood samples should be provided for gene mutation detection during the screening period. It is recommended to provide tumor tissue samples.
- 7. Male subjects whose partner is women of childbearing potential (WOCBP) are required to use highly effective contraception from the date of signing the informed consent until 3 months after the last dose of the investigational drug.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06568094；登记信息更新于 2026-09-17。